Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study

BACKGROUND: Tislelizumab combined with radiotherapy as a salvage treatment for patients with end-stage metastatic castration-resistant prostate cancer (mCRPC) is not reported. This study aimed to describe a protocol to evaluate the safety and efficacy of multisite radiotherapy combined with tisleliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ke, Wang, Yuqing, Chen, Ye, Zhu, Jingjie, Qi, Xiaohui, Wang, Yachen, Zou, Yanqiu, Lu, Qiuhan, Li, Zhiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300836/
https://www.ncbi.nlm.nih.gov/pubmed/35875078
http://dx.doi.org/10.3389/fonc.2022.888707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300836/
https://www.ncbi.nlm.nih.gov/pubmed/35875078
http://dx.doi.org/10.3389/fonc.2022.888707

Ejemplares similares